67 posts
Unapproved Research Peptides: FDA Has Cleared 100+ Peptides, But Clinic Supply Chain Risks Persist
An analysis highlights risks of unapproved research peptides, including contamination and hospitalization reports, as clinics face supply chain diligence questions.
10 月 30, 2026Peptide Hype Outpaces Evidence as FDA Panel Weighs Compounding List
A Good Housekeeping fact-check says peptide marketing has outpaced human evidence, as an FDA advisory panel weighs adding some largely unproven peptides to a compounding list.
10 月 30, 2026Semaglutide Patent Cliff 2026: Generic GLP-1 Peptides to Reshape Supply Chains
Semaglutide patents expire in 2026 in India, China and Brazil, opening the GLP-1 market to generics. Here is what it means for peptide supply, clinics and research buyers.
10 月 30, 2026MHT Plus Semaglutide Tied to Greater Weight Loss in Menopause Study
A non-peer-reviewed analysis of about 2,400 women over 45 links menopausal hormone therapy plus semaglutide to greater sustained weight loss, while tirzepatide results fell short of significance.
10 月 29, 2026Retatrutide Phase 3 Data: Triple Agonist Cuts HbA1c, Weight in T2D
A phase 3 trial in The Lancet reports retatrutide cut HbA1c by 1.69–1.94 points and weight by up to 15.3% over 40 weeks, with no head-to-head comparison to Ozempic or Mounjaro.
10 月 29, 2026DROFEN Completes FAT on 160 pcs/min Insulin Pen Assembly Line for GLP-1 CDMOs
DROFEN MACHINERY completed FAT on a 160 pcs/min insulin pen assembly line and markets a single-source package for CDMOs. Client data and independent verification were not disclosed.
10 月 28, 2026What Services Does PeptideSCM Provide? Peptide Therapy, Sourcing, Manufacturing, and Cross-Border Supply Chain Support
PeptideSCM is a resource discovery and business consulting platform for peptide medical care, research, manufacturing, and international supply. This guide covers all 20 services we provide: finding U.S. peptide therapy clinics and telehealth platforms, evaluating 503A and 503B pharmacies, sourcing research peptides and Chinese API suppliers, cartridge and lyophilization equipment, international logistics and customs support, and legal and commercial help for cross-border trade.
10 月 28, 2026GLP-1 Drug Guide 2026: No Generic Semaglutide as Oral Wegovy and Pipeline Peptides Reshape Market
A January 2026 GLP-1 drug guide maps approved brands, generic status and the 2026 pipeline, confirming no FDA-approved generic semaglutide or tirzepatide.
10 月 28, 2026CagriSema Hits 25% Weight Loss in Women, But Stays Unapproved
A post-hoc REDEFINE 1 analysis links CagriSema to 25% weight loss in women, but the dual peptide remains unapproved and failed a tirzepatide head-to-head test.
10 月 26, 2026Retatrutide’s 28.3% Weight Loss Meets the GLP-1 Plateau Test
Retatrutide produced 28.3% weight loss at 80 weeks in TRIUMPH-1, but experts caution no trial yet shows it breaks the GLP-1 plateau in patients already on semaglutide or tirzepatide.
10 月 26, 2026Compounded Tirzepatide Recall: Apothecary Pharma Pulls 22 Vials After FDA Sterility Warning
Apothecary Pharma is recalling 22 vials of compounded tirzepatide over sterility concerns following a December 2025 FDA warning letter, with the action classified as Class II.
10 月 26, 2026Semaglutide in Indian Teens Cuts Weight 17.2% in Real-World Peptide Data
A 40-patient Indian retrospective study links once-weekly semaglutide to a 17.2% mean weight reduction in adolescents, with implications for GLP-1 clinics and peptide supply chains.
10 月 26, 2026